29Jan

EKF signs DiaSpect Tm U.S. distribution agreement with McKesson to launch McKesson Consult® Hb analyzer

EKF_1

Cardiff, UK – 29th January 2019 – EKF Diagnostics, the global in vitro diagnostics company, announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc. for the Company’s hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm. McKesson is the oldest and largest healthcare company in the U.S., serving more than 50% of U.S. hospitals and 20% of physicians. The DiaSpect Tm is the world’s fastest hemoglobin analyzer and will be sold in the U.S. from February 2019 by McKesson under its own branded line, as the McKesson Consult® Hb analyzer.

The agreement follows US Food and Drug Administration 510(k) clearance and CLIA waiver by statute for the DiaSpect Tm in April 2018, approving the product for use in point of care (POC) and Certificate of Waiver settings, such as physicians’ offices, clinics and other non-traditional laboratory locations. Prior to signing the agreement McKesson also undertook its own comprehensive evaluation of the POC hemoglobin analyzer, confirming its quality and reliability.

Commenting, Julian Baines, CEO of EKF Diagnostics, said, “The DiaSpect Tm gives physicians access to an easy-to-use, accurate and portable hemoglobin measurement system able to deliver laboratory quality results at the point-of-care within seconds. This agreement with McKesson allows us to offer our innovative POC hemoglobin analysis technology to physicians and childcare specialists across the U.S. through the market’s leading and most established healthcare distribution player. It also affirms the quality of EKF’s product and manufacturing capabilities.”

Christopher Rogers, Vice President, McKesson Brands, added, “We are excited to partner with EKF Diagnostics to offer this industry leading technology, providing physicians a convenient design and fast, accurate results for onsite blood testing. The McKesson Consult® Hb analyzer demonstrates McKesson Brands’ ongoing commitment to offering value-oriented lab solutions to assist our customers in providing improved care for their patients.”

The palm-sized, lightweight DiaSpect Tm provides users in a variety of care settings with laboratory accurate hemoglobin measurements (precision: CV ≤1%) within two seconds of its whole blood-filled cuvette being inserted for analysis. This ensures immediate and robust hemoglobin results for patient health checks and anemia screening at the point of care.

Based on its FDA categorization, DiaSpect Tm can be used in a range of environments, as well as by a broad scope of health care personnel. Essential for this, it is highly user-friendly requiring minimal training. For example, the analyzer’s sampling microcuvette has been designed to collect a blood sample from any angle without forming air bubbles. The user simply collects a capillary or venous blood sample of 10 µL in the cuvette before inserting straight into the analyzer. Also making it simple for POCT use, DiaSpect Tm is factory calibrated against the HiCN reference method in accordance with ICSH. It is ‘always on’ and ready to use with no re-calibration or maintenance necessary.

For more information on the DiaSpect Tm see: www.ekfdiagnostics.com/diaspect.html 

Related

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

Belgium, 16 May 2017 – Multiplicom, an Agilent Technologies Company, announced today the extended C...

Read More >

Abingdon Health Ltd (“Abingdon”) has announced its entry in the UK Parliamentary Review 2017 (“The Review”) has now been published.

While focusing on 12 key government policy areas, the Review, which is distributed to Policymakers i...

Read More >

Proteome Sciences plc announce Good Clinical Laboratory Practice Accreditation

Proteome Sciences are pleased to announce the receipt of Good Clinical Laboratory Practice (GCLP) ac...

Read More >

Reduce Your Costs for Biological Sample Transport

How do you package your send-away pathology samples? Are you spending too much time and money on pac...

Read More >

QIAGEN announces FDA approval of PartoSure

Germantown, Maryland, and Hilden, Germany, April 20, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prim...

Read More >

Novodiag® launch, a new diagnostic solution for infectious diseases.

Espoo, Finland, January 3rd, 2018 - Mobidiag, a Finnish molecular diagnostics company, launches Novo...

Read More >